Fibrosis, IPF and the search for better therapies

from BioSpace · host BioSpace

In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsGeorg Vo Beiske, CEO, Tribune TherapeuticsJonas Hallén, Co-Founder & CMO, Calluna PharmaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Episode metadata supplied by the publisher feed · Published May 7, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Fibrosis, IPF and the search for better therapies

0:00 18:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 18 minutes long.

When was this BioSpace episode published?

This episode was published on May 7, 2026.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!